D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
SYRE holding history
Spyre Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SYRE overviewAll 13F holders of SYREFull Q2 2026 holdings
- Shares (Q2 2026)
- 26,452
- Value
- $2.35M
- % of portfolio
- <0.1%
- Quarters held
- 7
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 26,452 | $2.35M | <0.1% | +26,452 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −476,404−100.0% | Sold out | Holders |
| Q2 2022 | 476,404 | $241.0K | <0.1% | +22,311+4.9% | Added | Holders |
| Q1 2022 | 454,093 | $1.04M | <0.1% | +226,585+99.6% | Added | Holders |
| Q4 2021 | 227,508 | $1.08M | <0.1% | +199,005+698.2% | Added | Holders |
| Q3 2021 | 28,503 | $227.0K | <0.1% | −17,478−38.0% | Reduced | Holders |
| Q2 2021 | 45,981 | $320.0K | <0.1% | −16,766−26.7% | Reduced | Holders |
| Q1 2021 | 62,747 | $497.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.